Biologics Contract Development Market - Global Industry Analysis

Biologics Contract Development Market

Biologics Contract Development Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2026

Category: Biotechnology Report Format : PDF Report Code: ZMR-5434 Status : Upcoming

Biologics Contract Development Market

Description

Global Biologics Contract Development Market: Overview

Biologics contract development is the comprehensive outsourcing service that manufactures biotechnology, pharmaceutical, and medical devices supporting biomaterials under the label of another company.

Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Global Biologics Contract Development Market: Growth Factors

Some of the significant factors that boost the global biologics contract development market are the surge in the adoption of advanced techniques for biological production, outsourcing the research & development tasks by pharma companies, and a well-suited environment for performing clinical trials. The surge in merger and collaboration activities increases the outsourcing of pharma and biopharma companies to expand in the developed and developing countries.

For instance, Thermo Fisher Scientific Inc. acquired Brammer Bio, a leader in contract development of cell and gene therapy, to empower its portfolio in gene therapy.

There has been a surge in diseases like cancer, neurology disorders, cardiovascular disorder, gynecological disorders, and ophthalmic disorders in recent years. The healthcare CDMOS emerged as a savior in patient care and many pharma leaders are making their contribution in inventing novel therapies for the efficient treatment of these diseases.

The increase in research and development investment for future advancements in technology fuels the market to grow significantly with high rates.

Biological contracts gradually shift to single-use bioreactors to facilitate the reduction in upfront costs and enhance manufacturing flexibility. Improved flexibility in manufacturing productivity increases the supply of biology and thus drives the global biologics contract development market.

Global Biologics Contract Development Market: Segmentation

The global biologics contract development market can be segmented into the source, product, disease, and region.

By source, the market can be segmented into mammalian, microbial, and others. The mammalian segment has the largest market share and is forecasted to witness significant growth rate in the coming years. The growth can be attributed to the usage of mammalian cells for protein synthesis to produce accurate post-transnational mammalian protein. Chinese mammalian cells are preferred the most for protein therapeutics and development for CMO cells.

The microbial cell segment is expected to witness a high growth rate over forecast years. The microbial cell lines are majorly used in the production of hormones, enzymes, cytokines, and others.

By product, the market can be segmented into cell line development and process development.

The process development segment holds the largest share in the global biologics contract development market. The process development can further be segmented into upstream, downstream, and others.

The upstream process includes the choosing of the right cell line, bioreactor system, operating dimensions, and culture medium.

The downstream process includes the testing and purification of a fermented medium having an inoculum. Many qualitative assessments like pharmaceutical analysis, physicochemical characterization, packaging, and validating polishing are included in the downstream process segment.

By disease, the market can be segmented into oncology, immunological disorders, cardiovascular disorders, hematological disorders, and others.

The oncology segment holds the largest market share.

The immunology segment is expected to witness high growth rate over the forecast years. There are growing cases of immune system dysfunction all over the world.

Global Biologics Contract Development Market: Regional analysis

North America has the largest share in the global biologics contract development market. The growth in the region can be attributed to the surge in research & development investments and the presence of global players locally. The growth of contract development (CDO) also attributes to the increase in outsourcing of various tasks & clinical trials and thus boosts the regional market.

Asia Pacific is expected to witness high growth rate over the forecast years. The growth can be attributed to the amendments done to change the evaluation standard of clinical trials and increased investment to improve the technology by the prominent industry players.

Global Biologics Contract Development Market: Competitive Players

Some of the prominent players in the global biologics contract development market are WuXi Biologics, AGC Biologics, Genscript Biotech Corporation, Abzena Ltd., SE Thermo Fisher (Patheon), Bionova Scientific, LakePharma, STC Biologics, Inc., Hansen, Fujifilm Diosynth Biotechnologies, KBI Biopharma, Boehringer Ingelheim BioXcellence, and AGC Biologics.

Global Biologics Contract Development Market: Regional Segment Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

What Reports Provides

  • Full in-depth analysis of the parent market
  • Important changes in market dynamics
  • Segmentation details of the market
  • Former, on-going, and projected market analysis in terms of volume and value
  • Assessment of niche industry developments
  • Market share analysis
  • Key strategies of major players
  • Emerging segments and regional markets
  • Testimonials to companies in order to fortify their foothold in the market.

Table Of Content

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed